Posterior Reversible Encephalopathy Syndrome in a Patient with Spinal Metastasis
Journal of Neurointensive Care · 2018
DOI: 10.32587/jnic.2018.00024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurointensive Care, 2018. Verfasst von Jin Wook Kim und 1 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Posterior reversible encephalopathy syndrome (PRES), also named reversible posterior leukoencephalopathy, is not a familiar term to neurosurgeon.The PRES is characterized by various kinds of neurologic signs and symptoms that include headache, seizure, altered mental status, lethalgy, visual loss and focal neurological disability.A 63-year-old female visited with upper back pain and both leg weakness.She has been receiving chemotherapy with gemcitabine and cisplatin for lung cancer with multiple bone metastasis.According to the imaging, we diagnosed the patient as T8 pathologic fracture.Five days after surgical decompression, she suddenly complained of visual loss.Magnetic resonance imaging(MRI) of the brain showed bilateral subcortical and cortical edema in the parieto-occipital area.Her MRI finding and symptoms suggested the PRES.Five days after conservative treatment, her visual disturbance was completely recovered.We believe that accurate and early detection of PRES and adequate treatment is very important for the patient having a history of chemotherapy.
Zitieren
APA
Kim, J. W., & Jeong, J. H. (2018). Posterior Reversible Encephalopathy Syndrome in a Patient with Spinal Metastasis. Journal of Neurointensive Care. https://doi.org/10.32587/jnic.2018.00024
Vancouver
Kim JW, Jeong JH. Posterior Reversible Encephalopathy Syndrome in a Patient with Spinal Metastasis. Journal of Neurointensive Care. 2018. doi:10.32587/jnic.2018.00024
BibTeX
@article{Kim2018,
author = {Kim, Jin Wook and Jeong, Ju Ho},
title = {Posterior Reversible Encephalopathy Syndrome in a Patient with Spinal Metastasis},
journal = {Journal of Neurointensive Care},
year = {2018},
doi = {10.32587/jnic.2018.00024}
}
EUVIMED